PAN-LEISHMANIASIS PROPHYLACTIC HUMAN VACCINE
Leishmaniasis is considered to be one of the most serious parasitic infections affecting humans worldwide and represents a major public health concern in Latin America, Asia, Africa, and southern Europe.
The team identified a cocktail of multi-epitope peptides that activate the immune system specifically to fight different species of Leishmania.
This project seeks to develop a new prophylactic vaccine solution against leishmaniasis to provide optimal vaccination coverage for the population, notably in southern countries and countries developing as a result of migration and military flows.
AVAILABLE TECHNOLOGY | Leishmanioses – Secretomes – Multi-epitope peptide vaccine